<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956576</url>
  </required_header>
  <id_info>
    <org_study_id>AC18094</org_study_id>
    <nct_id>NCT03956576</nct_id>
  </id_info>
  <brief_title>Apelin as a Potential Treatment for Chronic Kidney Disease</brief_title>
  <acronym>AlPaCKa</acronym>
  <official_title>Apelin as a Potential Treatment for Chronic Kidney Disease: The AlPaCKa Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kidney Cancer UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) affects 8-16% of the world's population, and is independently
      associated with cardiovascular disease (CVD). As renal function declines, rates of major
      adverse cardiovascular events, cardiovascular and all-cause mortality increase. In addition
      to hypertension, increased arterial stiffness is characteristic of CKD, a marker of CVD risk,
      and an independent predictor of mortality in CKD patients. The endothelium is an important
      regulator of arterial stiffness, and endothelial dysfunction is a feature of CKD and a
      predictor of CVD. Current treatment of CKD is limited and aims to reduce blood pressure and
      proteinuria through the use of angiotensin converting enzyme (ACE) inhibitors or angiotensin
      receptor blockers (ARB). However, many patients still progress to end-stage renal failure and
      often these patients die as a result of CVD.

      A novel peptide, apelin, is proposed to be a potential treatment for CKD, with additional
      cardiovascular benefits. The AlPaCKa study investigators will carry out forearm blood flow
      and renal clearance studies in 25 patients with CKD and 25 matched healthy volunteers to
      determine the effects of apelin on cardiovascular and renal parameters. It is hoped apelin
      will be confirmed as a potential future treatment for CKD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The apelins are a family of peptides whose most abundant isoform is [Pyr1]apelin-13. This
      binds to a single G protein coupled receptor known as 'APJ', which is widely expressed
      particularly in endothelium and cardiomyocytes. Apelin is the most powerful inotropic agent
      discovered to date, and apelin infusion into healthy humans leads to endothelium-dependent
      vasodilatation and BP lowering. Given its vasodilatory and inotropic effects, apelin is being
      investigated as a novel therapy for heart failure and pulmonary arterial hypertension, both
      of which are features of CKD. The apelin/APJ system is widely expressed in the human kidney
      (endothelium, smooth muscle cells, glomeruli) with a predominance in the renal medulla. It is
      recognised to have a role in fluid homeostasis, and apelin infusion in rodents leads to a
      dose-dependent diuresis but it is difficult to discriminate how much of this is due to renal
      vasodilatation as opposed to a direct tubular effect. However, it has been shown that apelin
      counteracts the antidiuretic effect of vasopressin at the tubular level. Evidence therefore
      suggests that apelin could have additional cardioprotective effects in CKD and could promote
      natriuresis and diuresis. To date there are no clinical studies of the actions of apelin in
      the kidney in health or CKD, or its effect on systemic haemodynamics in CKD.

      Twenty-five patients with CKD and 25 matched healthy volunteers will undergo forearm blood
      flow studies with acetylcholine, sodium nitroprusside and apelin to determine the local
      haemodynamic effects of apelin in CKD, specifically the effects on endothelial function. The
      same subjects will then complete two renal clearance studies during systemic apelin / placebo
      infusion (randomised and double-blinded), by standard renal para-aminohippurate and inulin
      clearance techniques. Blood and urine samples will be collected every 30 minutes. This will
      allow the effects of apelin on renal function, renal blood flow, proteinuria, natriuresis and
      diuresis to be demonstrated. Cardiovascular effects will be determined by systemic
      bioimpedance measures and pulse wave velocity. This study aims to open a new area of clinical
      research with apelin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in forearm blood flow</measure>
    <time_frame>1 hour</time_frame>
    <description>Venous occlusion plethysmography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in renal blood flow</measure>
    <time_frame>4 hours</time_frame>
    <description>Para-aminohippurate clearance study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in arterial stiffness</measure>
    <time_frame>1 hour</time_frame>
    <description>Pulse wave velocity measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in natriuresis</measure>
    <time_frame>4 hours</time_frame>
    <description>Urinary sodium excretion measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diuresis</measure>
    <time_frame>4 hours</time_frame>
    <description>Free water clearance measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>4 hours</time_frame>
    <description>Blood pressure monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proteinuria</measure>
    <time_frame>4 hours</time_frame>
    <description>Urinary protein excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in chorioretinal metrics as assessed by optical coherence tomography (OCT</measure>
    <time_frame>4 hours</time_frame>
    <description>Optical coherence tomography measurements</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Chronic Kidney Disease patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Forearm blood flow studies
- acetylcholine (7.5, 15, 30microgram/min), sodium nitroprusside (1, 2, 4microgram/min) and [Pyr1]apelin-13 (0.3, 1, 3, 10, 30, 100nmol/min). Incremental doses of each lasting 8 minutes with saline washout between drugs.
Renal clearance studies
Two standard para-aminohippurate (PAH) / inulin clearance studies with infusion of either apelin or placebo on each day.
Dose of PAH / inulin dependent on renal function. Continuous infusion lasting 7hours in total.
[Pyr1]apelin-13 infusion initial rate 30nmol/min for 1 hour; subsequently 300nmol/min for 2 hours.
Crossover design, so patients will receive both apelin and placebo infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Forearm blood flow studies
- acetylcholine (7.5, 15, 30microgram/min), sodium nitroprusside (1, 2, 4microgram/min) and [Pyr1]apelin-13 (0.3, 1, 3, 10, 30, 100nmol/min). Incremental doses of each lasting 8 minutes with saline washout between drugs.
Renal clearance studies
Two standard para-aminohippurate (PAH) / inulin clearance studies with infusion of either apelin or placebo on each day.
Dose of PAH / inulin dependent on renal function. Continuous infusion lasting 7hours in total.
[Pyr1]apelin-13 infusion initial rate 30nmol/min for 1 hour; subsequently 300nmol/min for 2 hours.
Crossover design, so patients will receive both apelin and placebo infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[Pyr]apelin-13</intervention_name>
    <description>Peptide [Pyr]apelin-13 infusion</description>
    <arm_group_label>Chronic Kidney Disease patients</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults &gt;18yrs

          -  Stable, non-diabetic chronic kidney disease stages 1 - 4 as defined by Kidney Disease:
             Improving Global Outcomes (KDIGO) 2012 classification (estimated Glomerular Filtration
             Rate (eGFR) &gt;15ml/min/1.73m2)

          -  Urinary protein excretion &gt;300mg/day (urine protein:creatinine &gt;30)

          -  Clinically optimised on an angiotensin converting enzyme inhibitor / angiotensin
             receptor blocker, or intolerant to these agents.

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Diabetes mellitus

          -  Overt cardiovascular disease

          -  Blood pressure &gt;160/100mmHg

          -  Estimated GFR of Â£15ml/min/1.73m2

          -  Renal transplant recipients

          -  Haemodialysis / peritoneal dialysis patients

          -  Serum albumin &lt;30g/L

          -  Patients receiving tolvaptan therapy for polycystic kidney disease

          -  Patients not medically fit to attend for study visits

          -  Patients without mental capacity or willingness to provide informed consent

          -  History of multiple and/or severe allergic reaction to drugs (including study drugs)
             or food

          -  Patients who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neeraj Dhaun, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fiona Chapman, MBChB</last_name>
    <phone>0131 242 3326</phone>
    <email>fchapman@ed.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neeraj Dhaun, PhD</last_name>
    <phone>0131 242 3326</phone>
    <email>bean.dhaun@ed.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Research Centre, Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neeraj Dhaun, PhD</last_name>
      <email>bean.dhaun@ed.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No data to be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

